CYP27A1

Across TCGA pan-cancer cohorts, CYP27A1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CYP27A1 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CYP27A1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYP27A1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

GBM, LUAD, and HNSC are the cancer types where CYP27A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.607	0.861	.004	9	view →
LUAD	DFS	Median	III,IV	0.305	0.702	.021	3	view →
HNSC	OS	Tertile	IV	0.788	0.942	.044	1	view →
CCRCC	OS	Tertile	All	1.000	0.901	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CYP27A1–GBM (DFS)

Open the GBM breakdown →